Vineeta Agarwala has been confirmed as one of the general partners running the firm's $750m Bio Fund III following nearly five years at corporate venturing unit GV.

Existing investor Gradient Ventures invested in a series B round that almost doubled the clinical research software provider's overall funding to $45m.

The biomedical commercialisation hub will invest $200,000 in four to six startups each year from University of Washington and other local centres of research.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Legend Capital contributed to a round that will fund progress of JenaValve's transcatheter aortic valve replacement towards US regulatory approval.

UPMC will invest some of its recently announced $1bn healthcare commercialisation budget to create a new pharmaceutical development firm.

McKesson Ventures co-led the first round to be disclosed by the clinical trial services provider, which will put the money into recruitment and improving its technology platform.

Chalmers University of Technology-founded baby ventilation monitor developer Monivent will join the Spotlight Stock Market in an IPO where 60% of shares have advance subscriptions in place.

University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.

The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.